Short Interest in Prenetics Global Limited (NASDAQ:PRE) Decreases By 17.6%

Prenetics Global Limited (NASDAQ:PRE - Get Free Report) was the target of a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 32,800 shares, a decrease of 17.6% from the February 13th total of 39,800 shares. Based on an average trading volume of 13,600 shares, the days-to-cover ratio is currently 2.4 days. Currently, 0.4% of the company's stock are sold short.

Hedge Funds Weigh In On Prenetics Global

An institutional investor recently bought a new position in Prenetics Global stock. Quinn Opportunity Partners LLC bought a new stake in Prenetics Global Limited (NASDAQ:PRE - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 12,339 shares of the company's stock, valued at approximately $72,000. Quinn Opportunity Partners LLC owned about 0.10% of Prenetics Global at the end of the most recent reporting period. Institutional investors and hedge funds own 25.01% of the company's stock.

Prenetics Global Trading Down 5.6 %

NASDAQ:PRE traded down $0.24 during trading hours on Friday, hitting $4.06. The company's stock had a trading volume of 7,454 shares, compared to its average volume of 37,919. The stock has a market capitalization of $49.55 million, a P/E ratio of -1.02 and a beta of -0.31. The stock has a fifty day moving average of $5.19 and a 200-day moving average of $4.95. Prenetics Global has a 52-week low of $2.85 and a 52-week high of $7.84.

Remove Ads

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $9.00 price objective on shares of Prenetics Global in a research report on Thursday, January 16th.

Prenetics Global Company Profile

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.